348526 RESULTS
COMMENT I share Jeremy Berg’s concerns and am deeply disappointed by the stance taken by Science and the AAAS, which appears to support the propagation of a damaging, biased, and unscientific narrative. Endorsing such a perspective risks distorting public underst
COMMENT A similar situation occurred with lecanemab, which was rejected by the EMA on the grounds that its benefits did not sufficiently outweigh the risks of potentially fatal ARIA events. In the case of donanemab, the decision appears to have been influenced by
COMMENT As Alzheimer’s science rapidly evolves, the scientific community has a responsibility to ensure the information presented to people facing Alzheimer’s disease or a related dementia is accurate and grounded in the latest science. However, increasingly, a s
EisaiUnited States
University College LondonUnited Kingdom
World Health Organization, Singapore
Eli LillyUnited Kingdom
PAPER Yang J, Ding H, Li Y, Ang TF, Devine S, Liu Y, Qiu W, Au R, Ma J, Liu C
PAPER Kim Y, Vaidya B, McInnes J, Zoghbi HY
PAPER Kozin MS, Kulakova OG, Kiselev IS, Semina EV, Kakotkin VV, Agapov MA, Favorova OO
PAPER Liu X, Zhou B, Chen Y, Lin J, Shao C, Chen L, Ruan B, Zhang X, Qian Y
PAPER Han X, Gong S, Gong J, Wang P, Li R, Chen R, Xu C, Sun W, Li S, Chen Y, Yang Y, Luan H, Wen B, Guo J, Lv S, Wei C
